US: AKBLF - ALK-Abelló A/S

الربحية لمدة ستة أشهر: +46.12%

جدول الترويج ALK-Abelló A/S


عن الشركة

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food.

مزيد من التفاصيل
It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including Anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. to develop, market and distribute allergy immunotherapy tablet for the treatment of grass pollen allergy. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета dkk
Сайт https://www.alk.net
Цена ао 27.03
تغير السعر يوميا: 0% (27.0328)
تغير السعر في الأسبوع: +9.89% (24.6)
تغير السعر شهريا: +24.69% (21.68)
تغير السعر خلال 3 أشهر: +33.17% (20.3)
تغير السعر على مدى ستة أشهر: +46.12% (18.5)
تغير السعر سنويا: +137.13% (11.4)
تغير السعر على مدى 3 سنوات: -94.45% (487)
تغير السعر على مدى 5 سنوات: -87.8% (221.5)
تغير السعر على مدى 10 سنوات: 0% (27.0328)
تغير الأسعار منذ بداية العام: +137.13% (11.4)

الاستهانة

اسم معنى درجة
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
المجموع: 2.5

كفاءة

اسم معنى درجة
ROA, % 0 0
ROE, % 0 0
المجموع: 0

توزيعات الأرباح

اسم معنى درجة
Div yield, % 0 0
DSI 1 10
المجموع: 1.61

واجب

اسم معنى درجة
Debt/EBITDA 0 10
المجموع: 10

دافع النمو

اسم معنى درجة
الربحية Revenue, % 47.34 6
الربحية Ebitda, % 268.55 10
الربحية EPS, % -833.33 0
المجموع: 3.2

مشرف مسمى وظيفي قسط سنة الميلاد
Mr. Claus Steensen Solje Executive VP, CFO & Member of Management Board 1972 (52 سنة)
Mr. Søren Daniel Niegel Executive VP of Commercial Operations & Member of Management Board 1971 (53 سنة)
Dr. Henriette Mersebach Executive VP Research & Development & Member of Management Board 1971 (53 سنة)
Ms. Katja Barnkob Thalund Project Director of Global CMC Development & Employee-elected Director 1969 (55 سنين)
Ms. Lise Lund Maerkedahl Project Director of Global Research & Employee-elected Director 1967 (57 سنين)
Mr. Peter Halling President & CEO 1977 (47 سنين)
Mr. Per Plotnikof VP of Corporate Communications, Investor Relations & Strategic Planning and Head of IR
Prof. Hendrik Kees Kam Nolte M.D., Ph.D. Senior Vice President of Research & Development - North America and International Markets
Mr. Christian G. Houghton Head of Product Supply
Mr. Peter Sejer Andersen Senior Vice President of Global Research & Drug Discovery

عنوان: Denmark, Horsholm, BOege AllE 6-8 - مفتوحة في خرائط جوجل, فتح خرائط ياندكس
موقع إلكتروني: https://www.alk.net